此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

JNJ-69086420 的研究,这是一种针对晚期前列腺癌的人激肽释放酶-2 (hK2) 标记的 Actinium-225 标记抗体

2026年11月2日 更新者:Janssen Research & Development, LLC

JNJ-69086420 的 1 期研究,这是一种 Actinium-225 标记的抗体,靶向人激肽释放酶-2 (hK2),用于治疗晚期前列腺癌

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion), to determine safety of JNJ-69086420 at the RP2D(s) as a combination therapy in Part 3 (combination therapy) and to determine safety of JNJ-69086420 at the RP2D(s) in participants with metastatic hormone-sensitive prostate cancer (mHSPC) in Part 4.

研究概览

研究类型

介入性

注册 (实际的)

144

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Phoenix、Arizona、美国、85054
        • Mayo Clinic Arizona
    • California
      • Duarte、California、美国、91010
        • City of Hope
    • Florida
      • Jacksonville、Florida、美国、32224
        • Mayo Clinic in Florida
    • Illinois
      • Chicago、Illinois、美国、60637
        • University of Chicago
    • Louisiana
      • Metairie、Louisiana、美国、70006
        • East Jefferson General Hospital
      • New Orleans、Louisiana、美国、70112
        • Tulane University Hospital & Clinics
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic Rochester
    • Nebraska
      • Omaha、Nebraska、美国、68130
        • XCancer Omaha / Urology Cancer Center
    • New York
      • New York、New York、美国、10065
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Cleveland、Ohio、美国、44106
        • Case Western Reserve University
    • Utah
      • Salt Lake City、Utah、美国、84112
        • University of Utah Huntsman Cancer Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria:

  • For Part 1, Part 2, Part 3: Metastatic castration resistant prostate cancer (mCRPC) with histologic confirmation of adenocarcinoma (adenocarcinoma with small-cell or neuroendocrine features is allowed) with prior exposure to at least one androgen receptor (AR) targeted therapy (for example [e.g.], abiraterone acetate, enzalutamide, apalutamide, darolutamide). In addition: Part 1: prior taxane or other chemotherapy is acceptable but not required. Part 2a: prior taxane or other chemotherapy required, Part 2b: no prior taxane or other chemotherapy, Part 2c: mCRPC that has progressed after prior treatment with lutetium Lu-177 vipivotide tetraxetan, with or without prior chemotherapy, Part 3: prior taxane or other chemotherapy is acceptable but not required & For Part 4a: metastatic HSPC, For Part 4b: disease that can be treated with less than or equal to (<=) 5 radiation fields and no visceral metastases
  • Parts 1, 2 & 3: Prior orchiectomy or medical castration, or, for participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analog (agonist or antagonist) prior to the first dose of study drug and must continue this therapy throughout the treatment phase. This criterion does not apply to Part 4
  • Palliative radiotherapy (e.g. soft tissue lesions) must be completed greater than (>) 2 weeks prior to start of study drug except for palliative radiotherapy for pain (e.g., bone pain), which may be used any time prior to first dose
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ functions as reflected in laboratory parameters

Exclusion Criteria:

  • Prior treatment with radium Xofigo (Ra 223 dichloride), strontium, samarium, or other radioconjugate therapy, other systemic anti-neoplastic therapy <=30 days prior to the first dose of study drug except for luteinizing hormone-releasing hormone agonists/antagonists or GnRH agonists/antagonists. Novel androgen axis drugs <=14 days prior to the first dose of study drug. In addition: Part 2b: Must not have received prior treatment with chemotherapy (eg, docetaxel) or poly ADP ribose polymerase (PARP) inhibitors, Part 2c: Prior treatment with lutetium Lu-177 vipivotide tetraxetan is required, but must have been completed >42 days prior to first dose of study drug, Part 3: Must not have received prior treatment with JNJ-78278343, Part 4: Must not have received ADT or AR-targeted therapy less than or equal to (<=) 56 days prior to first dose of study drug
  • Known history of myelodysplastic syndrome, leukemia, or hematological malignancy with features suggestive of myelodysplastic syndrome/acute myeloid leukemia at any timepoint
  • Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade <= 1 (except alopecia, radiation tissue fibrosis, or peripheral neuropathy)
  • Known allergies, hypersensitivity, or intolerance to JNJ-69086420 or its excipients and protein therapeutics. For Part 3, known allergies, hypersensitivity, or intolerance to JNJ-78278343 or its excipients or protein therapeutics
  • Active or chronic hepatitis B or hepatitis C infection

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Part 1: Dose Escalation

Participants will receive JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.

Participants will receive JNJ-69086420.

其他名称:
  • 锕-225-DOTA-h11B6
实验性的:Part 2: Dose Expansion

Participants in one or more cohorts will receive JNJ-69086420 at the RP2D(s) determined in Part 1.

Participants will receive JNJ-69086420.

其他名称:
  • 锕-225-DOTA-h11B6
实验性的:Part 3: Combination Therapy

Participants will receive JNJ-69086420 at the determined RP2D(s) and fixed dose of JNJ-78278343.

Participants will receive JNJ-69086420.

其他名称:
  • 锕-225-DOTA-h11B6

Participants will receive JNJ-78278343.

实验性的:Part 4: HSPC Expansion

Participants with HSPC will receive JNJ-69086420 at the RP2D(s) in Part 4(a), and JNJ-69086420 following stereotactic body radiation therapy in Part 4(b).

Participants will receive JNJ-69086420.

其他名称:
  • 锕-225-DOTA-h11B6

Participants will receive stereotactic body radiaition therapy.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
大体时间:Up to 2 years and 4 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 2 years and 4 months
Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
大体时间:Up to 2 years and 4 months

Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

Up to 2 years and 4 months
Number of Participants with AEs by Severity
大体时间:Up to 2 years and 4 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Up to 2 years and 4 months

次要结果测量

结果测量
措施说明
大体时间
Percentage of Participants with Prostate Specific Antigen (PSA) Response
大体时间:Up to 2 years and 4 months

PSA response rate is defined as the percentage of participants with a decline of PSA of 50 percent (%) or more from baseline and that is subsequently confirmed.

Up to 2 years and 4 months
Overall Response Rate (ORR)
大体时间:Up to 2 years and 4 months

ORR is defined as the percentage of participants who have a Partial Response (PR) or better according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 without evidence of bone progression according to Prostate Cancer Working Group 3 (PCWG3).

Up to 2 years and 4 months
Maximum Observed Serum Concentration/Radioactivity (Cmax) of JNJ-69086420
大体时间:Up to 2 years and 4 months

Cmax is defined as the maximum observed serum concentration/radioactivity of JNJ-69086420.

Up to 2 years and 4 months
Time to Reach Maximum Observed Serum Concentration/Radioactivity (Tmax) of JNJ-69086420
大体时间:Up to 2 years and 4 months

Tmax is defined as time to reach maximum observed serum concentration/radioactivity of JNJ-69086420.

Up to 2 years and 4 months
Area Under the Serum Concentration-time Curve From Time Zero to t Time (AUC[0-t]) of JNJ-69086420
大体时间:Up to 2 years and 4 months

AUC(0-t) is defined as the area under the serum concentration-time curve from time zero to t of JNJ-69086420.

Up to 2 years and 4 months
Number of Participants With Anti-JNJ-69086420 Antibodies
大体时间:Up to 2 years and 4 months

Number of participants with anti-JNJ-69086420 antibodies will be assessed to evaluate the potential immunogenicity.

Up to 2 years and 4 months
Part 3: Serum Concentration of JNJ-78278343
大体时间:Up to 2 years and 4 months

Venous blood samples will be collected for assessment of serum concentrations of JNJ-78278343.

Up to 2 years and 4 months
Part 3:Number of Participants With Anti-JNJ-78278343 Antibodies
大体时间:Up to 2 years and 4 months

Number of participants with anti-JNJ-78278343 antibodies will be assessed to evaluate the potential immunogenicity.

Up to 2 years and 4 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年11月12日

初级完成 (估计的)

2026年12月8日

研究完成 (估计的)

2026年12月30日

研究注册日期

首次提交

2020年11月20日

首先提交符合 QC 标准的

2020年11月20日

首次发布 (实际的)

2020年11月25日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅